

KEY ELEMENTS OF THE MDD GUIDELINE

- Screen annually for Depression (PHQ-2)
- Assess for Suicide Risk
- Obtain Standardized Symptom Score (PHQ-9)
- Diagnose based on DSM IV-TR Criteria
- Evaluate For Alternative Diagnosis (Bipolar, PTSD, Other)
- Initialize Treatment Strategies based on Symptom Severity
 - » Mild: watchful waiting and counseling
 - » Moderate (or mild not improving): monotherapy psychotherapy or medication
 - » Moderate to Severe: may require combination of psychotherapy and medication
- Shared decision in selection of treatment option considering patient preference
- Address psychoeducation and self-management for all patients
- Consult/refer to specialty for incomplete response, complicated MDD or patient request
- Monitor and follow-up especially when beginning therapy and changing of medication
- Use PHQ-9 to assess treatment response
- Continue therapy (9-12 months) to prevent relapse
- Consider long-term maintenance to prevent reoccurrence

Algorithm A: Assessment and Diagnosis




TABLE A-1	Screening for Depression (PHQ-2)	
	<i>Over the last two weeks, have you been bothered by any of the following problems?</i>	
	Yes	No
	Little interest or pleasure in doing things?	✓
	Feeling down, depressed, or hopeless?	✓

If the patient responded "yes" to either question, consider asking more detailed questions or using PHQ-9 patient questionnaire. (Table A-4)
If the patient's response to both questions is "no", the screen is negative.

TABLE A-2	Assessment for Dangerousness
1. Assess Threat to SELF	
<i>ASK THE QUESTIONS:</i>	
	Are you feeling hopeless about the future/present?
	<i>IF YES ASK:</i>
	Have you had thoughts about taking your life?
	<i>IF YES ASK:</i>
	When did you have these thoughts and do you have a plan to take your life?
	Have you ever had a suicide attempt?
2. Assess Threat to OTHERS	
a.	Assess whether the patient has an active plan and method/means (e.g., weapons in the home)
b.	Assess whom the patient wishes to harm
c.	Assess whether the patient has ever lost control and acted violently
d.	Assess seriousness/severity of past violent behavior

TABLE A-3	Clinical Assessment of the Patient with MDD
• Medical history	• Psychosocial history
• Physical examination	• Drug inventory, including over-the-counter (OTC) drugs and herbals
• Mental status examination (MSE)	• Comorbid conditions
• Relevant laboratory tests	

TABLE A-4	Patient Health Questionnaire (PHQ-9)				
	<i>Over the last 2 weeks, how often have you been bothered by any of the following?</i>				
	Not at all	Several days	More than half the days	Nearly every day	
1	Little interest or pleasure in doing things?	0	1	2	3
2	Feeling down, depressed, or hopeless?	0	1	2	3
3	Trouble falling or staying asleep, or sleeping too much?	0	1	2	3
4	Feeling tired or having little energy?	0	1	2	3
5	Poor appetite or overeating?	0	1	2	3
6	Feeling bad about yourself—or that you are a failure or have let yourself or your family down?	0	1	2	3
7	Trouble concentrating on things, such as reading the newspaper or watching television?	0	1	2	3
8	Moving or speaking so slowly that other people could have noticed? Or the opposite—being so fidgety or restless that you have been moving around a lot more than usual?	0	1	2	3
9	Thoughts that you would be better off dead or of hurting yourself in some way?	0	1	2	3
Total Score _____ =		+	+		
10	If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?	<input type="checkbox"/> Not difficult at all <input type="checkbox"/> Somewhat difficult <input type="checkbox"/> Very difficult <input type="checkbox"/> Extremely difficult			

PHQ was developed by Drs. Spitzer, Williams, Kroenke and colleagues. PRIME-MD® is a trademark of Pfizer inc. Copyright© 1999 Pfizer Inc. All rights reserved. Reproduced with permission.

TABLE A-5	Symptom Severity Classification	
Severity Level	(PHQ-9) Total Score	Functional Impairment
Mild	5-14	Mild
Moderate	15-19	Moderate
Severe	≥ 20	Severe

Modifiers	
Complications	Co-occurring post traumatic stress disorder (PTSD), substance use disorder (SUD), psychosis, suicide risk, mania, significant social stressors, war related conditions
Chronicity	More than 2 years of symptoms despite treatment

The PHQ-9 assessment tool combined with a clinical interview should be used to obtain the necessary information about symptoms, symptom severity, and effects on daily functioning that is required to diagnose MDD based on DSM-IV-TR criteria.

TABLE A-6	DSM-IV Diagnostic Criteria for MDD
<i>MDD diagnosis is based on the following list of symptoms, and requires the presence of symptom 1, 2, or both; and at least 5 of 9 symptoms overall; these symptoms must persist for at least 2 weeks</i>	
1.	Depressed mood nearly every day for most of the day, based on self-report or observation of others
2.	Marked reduction or loss of interest or pleasure in all, or nearly all, activities for most of the day, nearly every day
3.	Significant non-dieting weight loss or weight gain (> 5% change in body weight)
4.	Insomnia or hypersomnia nearly every day
5.	Psychomotor agitation or retardation (should be observable by others)
6.	Fatigue/loss of energy nearly every day
7.	Feelings of worthlessness or excessive/inappropriate guilt (possibly delusional) nearly every day
8.	Diminished cognitive function (reduced ability to think or concentrate, or indecisiveness) nearly every day
9.	Recurrent thoughts of death and/or suicide, suicide planning, or a suicide attempt

TABLE A-7	Nomenclature for Clinical Depressive Conditions	
DSM-IV-TR	Diagnostic Criteria	Duration
Major Depression	At least 5 depressive symptoms* (must include either depressed mood or anhedonia)	≥ 2 weeks
Dysthymia	3 or 4 dysthymic symptoms [§] (must include depressed mood)	≥ 2 years
Depression NOS	Variables: all included disorders must cause clinically significant impairment of daily functioning but fail to meet the classification for major depression or dysthymia. Example: minor depression with 2 to 4 depressive symptoms	≥ 2 weeks

* Depressive symptoms - See Table A-4
 § Dysthymic symptoms are generally the same as major depressive symptoms, with the addition of feeling of hopelessness and the omission of suicidal ideation.

TABLE A-8	Pathobiologies Related to Depression	
Pathology	Disease	
Cardiovascular	Coronary artery disease; Congestive heart failure; Stroke; Vascular dementias	
Chronic Pain	Fibromyalgia; Low back pain; Bone pain	
Degenerative	Hearing loss; Neurodegenerative diseases (i.e. Alzheimer's, Parkinson's, Huntington's)	
Immune	HIV; Multiple sclerosis; Systemic lupus erythematosus; Sarcoidosis	
Metabolic/Endocrine (including renal and pulmonary)	Malnutrition; Vitamin deficiencies; Hypo/hyperthyroidism; Addison's disease; Diabetes Mellitus; Hepatic disease (cirrhosis); COPD; Asthma; Kidney disease	
Neoplasms	Of any kind, especially pancreatic or CNS	
Trauma	Traumatic Brain Injury; Amputation; Burn injuries	

TABLE A-9	Medication Induced Depression			
Class	Association	Class	Association	
ACE-inhibitors	+/-	Lipid-lowering agents	+/-	
Barbiturates	+	NSAIDs	+	
Benzodiazepines	+	Progesterone implants	+/-	
Beta-blockers	+/-	Reserpine, Clonidine, Methyl dopa	+	
Calcium channel blockers	+/-	Selective estrogen receptor modulators	+/-	
Interferon-α	+/-	Topiramate	+	
Interleukin-2	+	Varenicline (Chantix)	+	

TABLE A-10	Indications for Referral to Mental Health
<ul style="list-style-type: none"> • Evidence of psychotic features, past mania or hypomania • History of/Potential for Suicide/Violence • Unclear diagnosis (PTSD, SUD) • Signs of comorbid psychiatric conditions • Unable to treat patient in primary care • Need for psychosocial interventions • Patient preference 	



Algorithm B: Treatment, Re-assessment and Follow-up




TABLE B-1 Shared Decision & Treatment Plan		
Present Treatment Options	<ul style="list-style-type: none"> Present feasible treatment options Describe pros/cons of each approach 	
Discuss with Patient	<ul style="list-style-type: none"> Side effect profiles for antidepressants Availability of psychological counseling Description of psychological counseling 	
Elicit Patient Preference	<ul style="list-style-type: none"> Ask patient for their treatment preference 	

TABLE B-2 Treatment Strategies		
Severity	PHQ Score Functional Impairment	Initial Treatment Strategies
Mild	5-14 Mild	<ul style="list-style-type: none"> Watchful waiting Supportive counseling If no improvement after one month, consider antidepressant or brief psychotherapy counseling
Moderate	15-19 Moderate	<ul style="list-style-type: none"> Start with monotherapy of either antidepressants or psychotherapy, or a combination of both
Severe	> 20 Severe	<ul style="list-style-type: none"> May start with monotherapy of either antidepressants or psychotherapy; Should emphasize combination of both or multiple drug therapy
Complicated	Co-occurring PTSD, SUD, mania, or significant social stressors	<ul style="list-style-type: none"> Start with combination of medications and somatic interventions
Chronicity	> 2 years of symptomatology despite treatment	<ul style="list-style-type: none"> For Mild: start with monotherapy (antidepressants or psychotherapy), or a combination of both For Mod/Severe: combination or multiple drug therapy

Treatment Strategy Options Include:	
1. Psychoeducation and self-management (provide to all MDD patients)	
2. Watchful waiting	
3. Monotherapy (psychotherapy or pharmacotherapy)	
4. Combination psychotherapy and antidepressants	
5. Treatment of complex patients	
6. Somatic treatment	
7. Inpatient and residential	

TABLE B-3 Psychoeducation and Self-Management	
<i>Collaboratively choose one or two goals at a time.</i>	
Nutrition	Maintain a balanced diet.
Exercise	Strong evidence shows that exercise often has significant anti-depressant effects.
Bibliotherapy	Use of self-help texts.
Sleep Hygiene	Education on sleep hygiene should be included for patients exhibiting sleep disturbance.
Tobacco Use	Tobacco use has been demonstrated to impact the recovery of depression. Referral or treatment of nicotine dependence should be considered.
Caffeine Use	Excessive caffeine use may exacerbate some symptoms of depression.
Alcohol Use and Abuse	Even low levels of alcohol use have been demonstrated to impact recovery of depression; patients should be advised to abstain until symptoms remit.
Pleasurable Activities	Behavioral activation has been shown to have significant antidepressant effects.

TABLE B-4 First-Line Treatment Options	
Psychotherapies	<ul style="list-style-type: none"> Cognitive Behavioral Therapy (CBT) Interpersonal Therapy (IPT) Problem Solving Therapy (PST) <p>Recommended for patients who:</p> <ul style="list-style-type: none"> Prefer psychological counseling. Had a previous good response to psychological counseling. Cannot tolerate medications. Have a prior course of illness that is chronic or characterized by poor inter-episode recovery. <p>May be helpful for patients who:</p> <ul style="list-style-type: none"> Have partial response to full dose of an antidepressant; Have personality disorders; and/or Have complex psychosocial problems.
Pharmacotherapy	<p>Antidepressants</p> <ul style="list-style-type: none"> SSRIs SNRIs Bupropion Mirtazapine <ul style="list-style-type: none"> No evidence that any one medication is better than another Select based on side effects, cost, and availability

Agent	TABLE B-5a Antidepressant Dosing and Monitoring	
	Initial Dose	Titration Schedule [†]
SSRIs	Citalopram	20 mg once a day
	Escitalopram	10 mg once a day
	Fluoxetine	20 mg once a day
	Fluoxetine Weekly	90 mg once a week
	Paroxetine	20 mg once a day
SNRIs	Paroxetine CR	25 mg once a day
	Sertraline	50 mg once a day
DNRI	Duloxetine	60 mg as a single or divided dose
	Venlafaxine IR	37.5 mg twice a day
	Venlafaxine XR	75 mg once a day
SARIs	Bupropion IR	100 mg twice a day
	Bupropion SR	150 mg once a day
	Bupropion XR	150 mg once a day
aSSAs	Trazodone	50 mg three times a day
	Mirtazapine	15 mg daily at bedtime
TCAs	Nortriptyline	25 mg once a day or divided
	Desipramine	75 mg once a day or divided

[†]Recommended minimum time between dose increases; Duloxetine, Escitalopram, Fluoxetine, Paroxetine CR are not on the VA National Formulary. All antidepressants listed are FDA Pregnancy Category C, except paroxetine which is Category D. Desipramine and Nortriptyline have not been assigned a pregnancy category by FDA.

TABLE B-5b Consider Medication Side Effects									
Category	Drug	Anticholinergic Activity (muscarinic)	Sedation (H1)	Orthostatic Hypotension (alpha)	Cardiac Effects	GI Effects	Seizures	Weight Gain	Sexual Dysfunction
SSRIs	Citalopram	0	0/+	0	0	+++	0	0	+++
	Escitalopram	0	0/+	0	0	+++	0	0	+++
	Fluoxetine	0	0/+	0	0/+	+++	0/+	0/+	+++
	Paroxetine	0/+	0/+	0	0	+++	0	0/+	+++
	Sertraline	0	0/+	0	0	+++	0	0	+++
SNRIs	Duloxetine	0	0/+	0/+	0/+	+++	0	0/+	+++
	Venlafaxine	0	0	0	0/+	+++	0	0	+++
NDRIs	Bupropion	0	0	0	0	++	+++	0	0
NaSSAs	Mirtazapine	0	+++	0/+	0	0/+	0	0/+	0

TABLE B-6 Assessment of Treatment Response			
<ul style="list-style-type: none"> Symptom severity (PHQ-9) and risk for suicide Tolerability to treatment (Adverse effects) Adherence to treatment Medical problems influencing recovery Psychosocial barriers to therapy Reevaluate diagnosis and appropriate treatment 			

TABLE B-7 Assess Treatment Response with PHQ-9*			
Onset Response to Treatment	Minimal clinically significant: a change in PHQ-9 score of 25% Response to treatment: improvement in PHQ-9 score of 50% from baseline		
Full Remission	PHQ-9 score of 4 or less, maintained for at least 1 month		
Recovery	PHQ score of 4 or less, maintained for at least 6 months		

*For other assessment tools see Full Guideline

TABLE B-8 Treatment Response and Follow-up			
Step	Patient Condition	Options	Reassess [†]
1	Initial Treatment	See Table B-2	2 weeks*
2	Non response to initial low dose*	<ul style="list-style-type: none"> Increase dose Consider longer duration Switch Consider referral to specialty care 	4 to 6 weeks
3	Failed second trial of antidepressant	<ul style="list-style-type: none"> Switch Augment or combine Consider referral to specialty care 	8 to 12 weeks
4	Failed 3 trials including augmentation	<ul style="list-style-type: none"> Re-evaluate diagnosis and treatment Consider referral to specialty care 	12 to 18 weeks

* If treatment is not tolerable, switch to another antidepressant.
[†]Cumulative time from initial treatment.




TABLE B-9 Indications for Referral to Specialty	
<ul style="list-style-type: none"> Evidence of psychotic features, past mania or hypomania (Bipolar) Complicated depression with comorbidity (PTSD, SUD) Treatment resistance Primary care out of comfort zone Patient request 	